Lechleider Robert 4

What Happened
Robert Lechleider, Immunome's Chief Medical Officer, received awards on July 23, 2026 totaling 162,000 units: 54,000 shares represented by restricted stock units (RSUs) and 108,000 derivative securities (award reported as derivative). Both grants show an acquisition price of $0.00 (i.e., no cash was paid). These are compensation awards — not open-market purchases or sales.

Key Details

• Transaction date: 2026-07-23; Form 4 filed 2026-07-27 (filed on the SEC deadline, timely).
• Grant amounts and reported values: 54,000 RSUs @ $0.00 (acquired = $0); 108,000 derivative units @ $0.00 (acquired = $0).
• Shares owned after transaction: not specified in the information provided.
• Footnote F1 (RSUs): Each RSU converts to one share upon settlement; 25% of these RSUs vest and settle annually on each anniversary of the grant date, subject to continued service.
• Footnote F2 (derivative award): 25% of the option-like shares vest on July 23, 2027, then 1/36th of the remaining shares vest monthly thereafter, subject to continued service.
• Transaction code: A = Award/Grant (compensation).

Context
These awards are standard equity compensation signals rather than market trades. The RSUs will convert to shares only as they vest; the derivative award is subject to a typical multi-year vesting schedule and does not represent immediately tradable shares unless vested and exercised/settled. No cash was paid and no sale occurred.